{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 20,
  "pageCount": 40,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a matrix-like layout to map clinical trial phases and treatment strategies against patient segments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/20",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.91,
        "x": 0.047,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Clinical development matrix showing treatment lines (Neo-adjuvant, 1L, 2L, 3L) vs cancer types (HER2-low, HER2-positive, Beyond breast cancer)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e98c6a48-ce25-4dec-87aa-e03f596865e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.46,
        "x": 0.047,
        "y": 0.825
      },
      "kind": "source-note",
      "text": "1. Hormone-receptor positive 2. Cyclin-dependent kinase 4/6 inhibitor 3. Hormone-receptor negative 4. Colorectal cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fa80154-1d68-41ea-8a6e-8cd758233ec8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.535,
        "x": 0.047,
        "y": 0.202
      },
      "kind": "title",
      "text": "Opportunities across breast cancer, HER2-low and other tumours",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2804276-2282-4847-9b0c-af70bcf78def",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.435,
        "x": 0.047,
        "y": 0.145
      },
      "kind": "title",
      "text": "Enhertu: clinical development programme",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "980b8d81-85ab-4660-a410-01d9376d4da9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "4c8cbecd-5430-42c3-ade7-88d8630c1695",
      "evidence": "diagram/process: Clinical development matrix showing treatment lines (Neo-adjuvant, 1L, 2L, 3L) vs cancer types (HER2-low, HER2-positive, Beyond breast cancer)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "roadmap",
      "slug": null,
      "matchId": "f6081931-b434-4d43-83a2-08b75f410484",
      "evidence": "The slide maps clinical development phases over time/treatment lines.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "6407b6da-054c-43a3-924f-c8af0ea8759b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document showcases AstraZeneca's pipeline and progress in various areas of oncology, providing satisfaction to investors.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}